Not in soy itself: a metabolite made by gut bacteria
Soy foods do not contain S-equol. It is produced in the colon by specific bacteria that reduce daidzein, a soy isoflavone, in three enzymatic steps, and only people who carry these bacteria can make it.
Most people cannot produce it themselves
Reviews put the share of producers at 20–30% of Western adults and 50–60% of Asian adults who eat soy regularly; among U.S. subjects only 14–17%. Soy isoflavones work only in producers, so supplementing S-equol directly bypasses the dependence on gut flora.
One configuration, one receptor preference
The human body produces only the S-enantiomer. S-equol prefers estrogen receptor β, with roughly nine times the affinity for ERβ as for ERα: ERβ mediates tissue-protective and anti-proliferative signalling, while ERα drives proliferative effects in breast and endometrial tissue. This preference underlies both the benefits seen in studies and the safety profile. Chemically synthesised R/S racemic mixtures do not share it.
Peak plasma concentration at about 1–3 hours, terminal half-life 7–8 hours, free fraction in plasma below 1%, and exposure proportional to dose across 10–320 mg. Half-life and high bioavailability together explain why most human studies use 10 mg/day.
Share of people able to produce equol
The figures are the share of people found to produce equol in each study. The first two rows are regional consensus figures from reviews; the remaining six are measured values from individual studies. The two Beijing rows are the same adults: 26.8% on their habitual diet, rising to 60.4% after eating soy for three consecutive days, which shows how strongly the share depends on habitual soy intake; Australian vegetarians are higher than non-vegetarians, and U.S. subjects are the lowest. Producer status is defined by the urinary S-equol to daidzein ratio reaching a threshold. Sources: Setchell 2010 (review) · Liu 2010 (Beijing, n=183) · Iino 2019 (Hirosaki, Japan, n=1,044) · Setchell & Cole 2006 (Australia, vegetarians n=29 / non-vegetarians n=12) · Akaza 2004 (U.S., controls 14%, cases 17%).
Existing third-party human research on S-equol
900+
Cumulative subjects in 9 human studies
9
Human studies · hot flushes · bone metabolism · skin · vaginal health · safety
7–8h
Terminal half-life · supports once-daily dosing
10–320mg
Single-dose range in Phase I · all tolerated
1yr
Longest randomised controlled trial · no change in endometrium or hormones
A summary of the nine human studies of S-equol (design, dose, outcomes, test material and source) is provided in the S-equol product brochure. None of the third-party studies above used NaturEQ™ as the test material, and some were funded by the relevant manufacturers; the mechanisms and findings described are a synthesis of published literature and do not constitute disease claims.